Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Ligand selectivity may directly be related to
2022-08-02

Ligand selectivity may directly be related to the conformational landscape explored by GPCRs despite that most GPCRs do not require dimerization for ligand recognition (Mary et al., 2012). Monomer FPRs have traditionally been perceived as receptors that can recognize N-formyl peptides and LXA4. This
-
Glucose induced nuclear translocation of several enzymes inc
2022-08-02

Glucose-induced nuclear translocation of several enzymes, including GK, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), muscle GS, aldolase, lactate dehydrogenase (LDH) and phosphoglycerate kinase (PGK) is a well-known phenomenon. Additional functions have been proposed for these enzymes in the nu
-
Hyperhomocysteinemia HHcy is a clinical condition characteri
2022-08-02

Hyperhomocysteinemia (HHcy) is a clinical condition characterized by increased levels of plasma homocysteine (Hcy) and a well-known risk factor for CVDs. Hcy is a sulfur-containing non-protein amino Clarithromycin mg formed during the intracellular conversion of methionine to cysteine. Previous stu
-
Despite the increased risk for infections and the widespread
2022-08-02

Despite the increased risk for infections and the widespread availability of vaccines, reported vaccine coverage rates among HIV-infected adult patients are low [17], [18], [19], [20], [21]. Data from two studies in the United States suggested that influenza vaccination coverage among HIV-infected p
-
MK cyclobutylpiperidin yl oxyphenyl methyl trifluoromethyl q
2022-08-01

MK-3134 (3-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-methyl-5-(trifluoromethyl)quinazolin-4-one) was synthesized by Merck, as the structurally constrained analogue of MK-0249 (Nagase et al., 2008). This H3R inverse agonist has MW 457.49, seven HBA, and MLogP 4.58, with one violation in terms of dr
-
br Introduction Histamine was generally accepted as a
2022-08-01

Introduction Histamine was generally accepted as a neurotransmitter in 1984, when histamine was first identified to be located in tuberomamillary nucleus (TM) of the brain (Watanabe et al., 1984). In mammals, histaminergic neurons play an important role in regulating multiple physiological activi
-
Ac-IETD-AFC synthesis In addition recent research shows that
2022-08-01

In addition, recent research shows that HK2 contributes to the inhibition of apoptosis through the suppression of the formation of mitochondrial permeability transition pores in association with voltage-dependent anion channel (VDAC) protein [11]. We also found that AKT2 mediates HK2 resistance to a
-
br Funding This study was supported by grants in
2022-08-01

Funding This study was supported by grants-in-aid for scientific research from the Japan Society for Promotion of Science (grant 16K186462 to Dr. Tomizawa, grant 16K19989 to Dr. Kobayashi, and grant 16H05433 to Dr. Mitsudomi) and a research grant from Boehringer-Ingelheim (to T. Mitsudomi). Co
-
br General aspects of HDACs br General aspects
2022-07-30

General aspects of HDACs General aspects of HDAC inhibitors Based on the previous elements, inhibitors designed for HDAC have in common a well-admitted pharmacophore model (Fig. 7A). This model is composed of a zinc binding group (ZBG), attached to a linker chain mimicking the lysine side chai
-
The endocytic inhibitors MDC and CPZ and dynamin GTPase
2022-07-30

The endocytic inhibitors MDC and CPZ and dynamin GTPase blocker (dynamin mutant) have been shown to significantly decrease the intracellular accumulation of cGMP. Moreover, earlier reports suggested that G-protein-coupled receptor (GPCRs) continue to signal by generating cAMP throughout internalizat
-
Over the last few years experimental evidence for
2022-07-30

Over the last few years, experimental evidence for the involvement of Epac1 in cancer progression is beginning to emerge (Almahariq et al., 2015, Banerjee and Cheng, 2015, Parnell et al., 2015, Parnell et al., 2015, Schmidt et al., 2013). For example in melanoma cells, silencing of Epac1 attenuates
-
These and other observations presented
2022-07-30

These and other observations presented in the elegant, rigorous study by Thomas et al. (2018) clarify a puzzling enigma regarding the Rab specificities of yeast TRAPP complexes and further highlight an important though under-appreciated role for the C-terminal HVD of Rabs in GEF substrate selection.
-
GSTP has an antiapoptotic activity that is mediated by the
2022-07-30

GSTP1 has an antiapoptotic activity that is mediated by the inhibitory interaction with JNK1. Our data suggest that GSTP1 treatment is associated with a significant down-regulation of caspase expression. This might explain the reduction in infarct-related cardiomyocyte death and saving the cardiomyo
-
Despite the association with asthma it is not surprising
2022-07-30

Despite the association with asthma, it is not surprising that we did not find a relation between the percent predicted FEV1 and SNPs in GSNOR. FEV1 measured on a routine clinic visit is likely to be normal in most asthmatic children. FEV1 in children reflects a complex mix of factors in the growth
-
Pharmacologic approaches of inhibiting GSNOR activity have
2022-07-30

Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications
16184 records 418/1079 page Previous Next First page 上5页 416417418419420 下5页 Last page